-
Featured Authors
-
Archives
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: patent
Patently Biotech’s Top 5 Articles of 2012
2012 has been an eventful year for biotech IP issues. Below are the top 5 articles and from Patently Biotech in 2012. Click on the links to read the full articles. 1. The Real Reason Why Salk Refused to Patent the Polio Vaccine A guest writer in a recent article in the Wall Street Journal repeated the oft quoted Jonas Salk statement about his Polio vaccine: “There is no patent. Could you patent the sun?” Many use this statement Read More >
Traditional Knowledge and Genetic Resources: India Misses the Mark
India recently asked the global community for comments on its “Draft Guidelines for Processing of Patent Applications Relating to Traditional Knowledge and Biological Material.” BIO was very active in their support of the goals of the Convention on Biological Diversity and “believes that a practical and workable Access and Benefit Sharing regime will benefit both the owner and the user of genetic resources and help countries to utilize their resources to develop their economies.” BIO Read More >
The ‘Access to Medicines’ Debate: Throwing Patients Without Cures Under the Proverbial Bus
The vast majority of the world’s patients remain completely forgotten in the ‘access to medicines’ debate. Many fail to understand how that elimination will affect the development of the cures and treatments of tomorrow, especially for rare diseases, cancers, and other serious unmet medical conditions. The Forgotten: 25 million Americans suffer from nearly 7000 rare diseases. 30 million European Union citizens suffer from between 6000 to 8000 rare diseases, 80% of which are of genetic origin Read More >
BIO Voices Agree: Intellectual Property Delivers
Over the last year, the U.S. Chamber of Commerce’s Global IP Center (GIPC) has met with entrepreneurs from around the world to get their personal stories on what it takes to become a breakthrough innovator in the 21st century. While the products that these innovators create come in many shapes and sizes, all of those we’ve come into contact with—many of whom from the annual BIO International Convention—have displayed a resounding respect for and interest Read More >
Novartis at India Supreme Court: Evergreening Myths and Patent Reality
Novartis will go before India’s Supreme Court on September 11, 2012 challenging the refusal by the Indian Patent Office to grant a patent on its cancer drug Glivec. The Indian Patent Office rejected Novartis’ application under a provision in Indian law which is aimed at guarding against so called “patent evergreening.” BIO has written two posts deconstructing the myth of patent evergreening. 1. Patent “Ever-Greening”: Novartis Confronts Patent Myth in India 2. Patent Evergreening in Read More >
